Blog

Optimi Health to Supply MDMA for Psychedelic Research at Tel Aviv University

Mar 26 • 3 min read

VANCOUVER, British Columbia, March 26, 2024 (GLOBE NEWSWIRE) — Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN), a leading Health Canada licensed psychedelics pharmaceutical manufacturer, specializing in controlled substances such as natural psilocybin and MDMA, is thrilled to announce it has entered an international MDMA supply agreement with The Institute for Psychedelic Research at Tel Aviv…

PharmAla Biotech Signs Sale Agreement with Numinus

Mar 26 • 2 min read

TORONTO, March 26, 2024 (GLOBE NEWSWIRE) — PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA, OTC:MDXXF), a biotechnology company focused on the research, development, and manufacturing of LaNeo™ MDMA and novel derivatives of MDMA (MDXX class molecules), is pleased to announce that it had entered into a binding sales agreement with Numinus Wellness Inc. (“Numinus”) (TSX: NUMI,…

Psyence Group Announces the Closing of the Previously Announced Strategic Restructuring of Its Non-Clinical Business

Mar 26 • 5 min read

TORONTO, March 26, 2024 (GLOBE NEWSWIRE) — Further to the announcement by Psyence Group Inc (“Psyence” or the “Company“) (CSE:PSYG) of its plans for the strategic restructuring of its non-clinical business through a conditional M&A transaction (the “Transaction“), Psyence is pleased to announce that the conditions to implement the Transaction have been met and that the Transaction has closed. Psyence has built…

PharmAla Biotech Holdings Inc. Announces Joint Venture with Cortexa Pty. Ltd

Mar 25 • 2 min read

PharmAla Biotech Holdings Inc. announced that, through its joint venture, Cortexa Pty. Ltd. (Cortexa), in what is an Australian and the Company believes a world first, has supplied GMP Psilocybin for therapeutic use outside of a clinical trial to a patient under the authorized prescriber scheme. The patient was being treated with Psilocybin for treatment…

Insurance Coverages To Help Bring Psychedelic Treatments to Market

Mar 22 • 4 min read

The revitalization of psychedelic substances for therapeutic applications has ignited significant interest in their potential as breakthrough treatments, driving a flurry of research and efforts to introduce these therapies into the market. In the United States, the journey to market for regulated substances is stringent, requiring extensive research, clinical tests, and trials overseen by the…

Pages: 123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113114115116117118119120121122123124125126127128129130131132133134135136137138139140141142143144145146147148149150151152153154155156157158159160161162163164165166167168169170171172173174175176177178179180181182183184185186187188189190191192193194195196197198199200201202203204205206207208209210211212213214215216217218219220221222223224225226227228229230231232233234235236237238239240241242243244245246247248249250251252253254255256257258259260261262263264265266267268269270271272273274275276277278279280281282283284285286287288289290291292293294295296297298299300301302303304305306307308309310311312313314315316317318319320321322323324325326327328329330331332333334335336337338339340341342343344345346347348349350351352353354355356357358359360361362363364365366367368369370371372373374375376377378379380381382383384385386387388389390391392393394395396397398399400401402403404405406407408409410411412413414415416417418419420421422423424425426427428429430431432433434435436437438439440441442443444445446447448449450451452453454455456457458459460461462463464465466467468469470471472473474475476477478479480481482483484485486487488489490491492493494495496497498499500501502503504505506507508509510511512513514515516517518519520521522523524525526527528529530531532533534535536537538